FLAP Modulators for Leukotriene-Mediated Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective FLAP modulators with pharmacokinetic and pharmacodynamic properties suitable for use as human pharmaceuticals to address various diseases and disorders mediated by leukotrienes, including respiratory, cardiac, cardiovascular, autoimmune, allergic, and carcinogenesis conditions, as existing treatments have limitations in efficacy and specificity.
Innovation Solution
Development of novel compounds, such as those represented by Formula (I), which act as FLAP modulators, including inhibitors, for use in pharmaceutical compositions to treat or prevent diseases and disorders associated with leukotriene activity, specifically targeting conditions like asthma, atherosclerosis, autoimmune diseases, and cancer, by administering therapeutically effective amounts of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for leukotriene-mediated diseases, then treatment coverage is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of FLAP modulators through various substituents (R1-R6, L, ring A) to optimize both efficacy and specificity. By systematically varying molecular parameters such as substituent types, positions, and configurations, the invention achieves compounds with improved therapeutic effectiveness and enhanced specificity for FLAP-targeted diseases compared to existing treatments
Solution Approach 2:
The patent employs composite materials principle by creating complex molecular structures that combine multiple functional groups and substituents into a unified FLAP modulator compound. These composite molecular structures (Formula I with various R groups and ring systems) work synergistically to achieve both high efficacy and specificity for leukotriene-mediated diseases, overcoming the limitations of simpler existing treatments
2Reliability
If novel FLAP modulators are developed to improve efficacy, then therapeutic benefits increase, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex FLAP modulator molecule into distinct modular components (core structure with Formula I, various substituents R1-R6, linker L, and ring A). This modular architecture allows systematic optimization of each component's contribution to therapeutic benefit while managing overall development complexity through structured molecular design
Solution Approach 2:
The patent implements local quality by assigning specific functional roles to different parts of the molecular structure. Each substituent (R1-R6) and structural element (L, ring A) is optimized for its local function - some regions enhance binding affinity to FLAP, others improve pharmacokinetic properties, and specific groups provide metabolic stability. This localized optimization achieves high therapeutic benefits while managing complexity through functional specialization
Data Source
AI summary
The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.